Antibiotic Development for Multidrug-Resistant ESKAPE Pathogens: Focused on designing and synthesizing novel antibiotics to combat multidrug-resistant pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.
Antibiotic Adjuvants for Repurposing Existing Therapies: Developing adjuvant molecules that enhance the efficacy of existing antibiotics, offering new strategies to overcome resistance in multidrug-resistant pathogens.